BioMarin Pharmaceutical Inc. (BMRN): A Potential 10x Investment by 2030
BioMarin's innovative pipeline may lead to significant stock growth by 2030, focusing on therapies for rare genetic diseases.
Editorial Staff 10 days ago
3 articles tagged with "Pharmaceuticals"
BioMarin's innovative pipeline may lead to significant stock growth by 2030, focusing on therapies for rare genetic diseases.
Replimune is set to make a third attempt for FDA approval of its drug, while Pfizer has recently secured a deal in China, highlighting ongoing developments in the pharmaceutical sector.